A key health ministry advisory panel will discuss on January 26 whether to back approval for Nobelpharma’s new hypozincemia treatment and an additional chronic kidney disease (CKD) indication for Nippon Boehringer Ingelheim’s Jardiance (empagliflozin). The Pharmaceutical Affairs and Food Sanitation…
To read the full story
Related Article
- Jardiance Filed in Japan for Chronic Kidney Disease: BI/Lilly
February 1, 2023
REGULATORY
- MHLW Issues Q&A on Conditional Approval System
May 1, 2026
- Panel Backs Proposal to Allow Antibody Drugs Like Beyfortus in NIP
May 1, 2026
- METI Clarifies Naphtha Comments, Reaffirms Medical Priority
April 30, 2026
- Japan Minister Rules Out Full Self-Pay for OTC-Like Drugs
April 30, 2026
- Govt’s Bio-WG Wraps Up Biopharma Investment Roadmap Draft
April 30, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





